163 related articles for article (PubMed ID: 1647871)
1. Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes.
Möller SA; Reisfeld RA
Cancer Immunol Immunother; 1991; 33(4):210-6. PubMed ID: 1647871
[TBL] [Abstract][Full Text] [Related]
2. Re-targeting of human lymphocytes expressing the T-cell receptor gamma/delta to ovarian carcinoma cells by the use of bispecific monoclonal antibodies.
Ferrini S; Prigione I; Mammoliti S; Colnaghi MI; Ménard S; Moretta A; Moretta L
Int J Cancer; 1989 Aug; 44(2):245-50. PubMed ID: 2527207
[TBL] [Abstract][Full Text] [Related]
3. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
[TBL] [Abstract][Full Text] [Related]
4. Bispecific monoclonal antibodies directed to CD16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones.
Ferrini S; Prigione I; Miotti S; Ciccone E; Cantoni C; Chen Q; Colnaghi MI; Moretta L
Int J Cancer; 1991 May; 48(2):227-33. PubMed ID: 1826900
[TBL] [Abstract][Full Text] [Related]
5. Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells.
Pupa SM; Canevari S; Fontanelli R; Ménard S; Mezzanzanica D; Lanzavecchia A; Colnaghi MI
Int J Cancer; 1988 Sep; 42(3):455-9. PubMed ID: 2971021
[TBL] [Abstract][Full Text] [Related]
6. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
[TBL] [Abstract][Full Text] [Related]
7. Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation.
Jacobs N; Mazzoni A; Mezzanzanica D; Negri DR; Valota O; Colnaghi MI; Moutschen MP; Boniver J; Canevari S
Cancer Immunol Immunother; 1997 Jul; 44(5):257-64. PubMed ID: 9247560
[TBL] [Abstract][Full Text] [Related]
8. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
Wimberger P; Xiang W; Mayr D; Diebold J; Dreier T; Baeuerle PA; Kimmig R
Int J Cancer; 2003 Jun; 105(2):241-8. PubMed ID: 12673686
[TBL] [Abstract][Full Text] [Related]
9. Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components.
Mezzanzanica D; Canevari S; Ménard S; Pupa SM; Tagliabue E; Lanzavecchia A; Colnaghi MI
Int J Cancer; 1988 Apr; 41(4):609-15. PubMed ID: 3258590
[TBL] [Abstract][Full Text] [Related]
10. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
[TBL] [Abstract][Full Text] [Related]
11. Induction of functional activities of human lymphocytes by monoclonal antibodies.
Melioli G; Prigione I; Merlì A; Cantoni C; Chen Q; Machi AM; Ferrini S
Ann Ist Super Sanita; 1991; 27(1):79-85. PubMed ID: 1835570
[TBL] [Abstract][Full Text] [Related]
12. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
[TBL] [Abstract][Full Text] [Related]
13. Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen.
van Dijk J; Warnaar SO; van Eendenburg JD; Thienpont M; Braakman E; Boot JH; Fleuren GJ; Bolhuis RL
Int J Cancer; 1989 Feb; 43(2):344-9. PubMed ID: 2521843
[TBL] [Abstract][Full Text] [Related]
14. Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice.
Garrido MA; Valdayo MJ; Winkler DF; Titus JA; Hecht TT; Perez P; Segal DM; Wunderlich JR
Cancer Res; 1990 Jul; 50(14):4227-32. PubMed ID: 2142014
[TBL] [Abstract][Full Text] [Related]
15. Bispecific antibody-directed antitumor activity of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus interleukin 2.
Nishimura T; Nakamura Y; Takeuchi Y; Gao XH; Tokuda Y; Okumura K; Habu S
Jpn J Cancer Res; 1991 Nov; 82(11):1207-10. PubMed ID: 1836455
[TBL] [Abstract][Full Text] [Related]
16. Development and characterization of a bispecific single-chain antibody directed against T cells and ovarian carcinoma.
Kriangkum J; Xu B; Gervais C; Paquette D; Jacobs FA; Martin L; Suresh MR
Hybridoma; 2000 Feb; 19(1):33-41. PubMed ID: 10768839
[TBL] [Abstract][Full Text] [Related]
17. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
18. Enhanced in vitro lysis of human ovarian carcinomas with activated peripheral blood lymphocytes and bifunctional immune heteroaggregates.
Donohue JH; Ramsey PS; Kerr LA; Segal DM; McKean DJ
Cancer Res; 1990 Oct; 50(20):6508-14. PubMed ID: 2145062
[TBL] [Abstract][Full Text] [Related]
19. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
[TBL] [Abstract][Full Text] [Related]
20. Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy.
Lamers CH; van de Griend RJ; Braakman E; Ronteltap CP; Bénard J; Stoter G; Gratama JW; Bolhuis RL
Int J Cancer; 1992 Jul; 51(6):973-9. PubMed ID: 1386349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]